FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
26/09/2022
Voltar para busca
Dado oficial do USPTO
ADRESTIA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ADRESTIA
ST13
US500000079307379Classe
1, 5, 42, 44
Pedido
79307379
Registro
6709002
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
38
Atualização mais recente
26/09/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 44
Data de depósito
08/12/2020
Data de registro
26/04/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/04/2022
Última transação
26/04/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
MURRAY, GEORGE WILLIAM
Unidade examinadora
N30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Adrestia Therapeutics Ltd
Representantes
BEN NATTER HAUG PARTNERS, LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals used in science; biological preparations for use in science; biochemicals for research use; cell lines and bio-production cell lines for scientificlaboratory or medical research; reagentsplasmids and assays for scientificgenetic and medical research; molecular biology research toolsin the nature of biological and biochemical reagents; biological and chemical reagents for research use; chemical reagents for scientific and research purposes; proteins in raw material form for scientific and medical research; gene extracts for research purposes; chemicals and biochemicals for drug discoverylead identificationdiagnosticsprofiling and research
Classe 5
Medical and veterinary preparations for the treatment of immune response disorderscardiovascular diseasesgenetic conditionscancerophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and infectious diseases in humans and animals; pharmaceutical substances and preparations for human use for the diagnosis and treatment of immune response disorderscardiovascular diseasesgenetic conditionscancerophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and infectious diseases; biopharmaceutical substances and preparations for human use for use in the diagnosis and treatment of immune response disorderscardiovascular diseasesgenetic conditionscancerophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and infectious diseases; reagentsdiagnostic preparations and therapeutic preparations in the nature of biologicalbiochemical and chemical reagents and vaccines for medical purposes; biological preparations for medical purposesfor the diagnosis and treatment of immune response disorderscardiovascular diseasesgenetic conditionscancerophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and infectious diseases; medical preparations for use in gene therapy; diagnostic preparations for medical purposes; therapeutic and diagnostic preparationssmall molecules for medical use
Classe 42
Medicalscientific and industrial research services in the field of cellscell therapiesgenome editinggenetic engineering and gene therapies and targeting therapies to individuals; pharmaceutical and biopharmaceutical research and development services; medical and pharmacological research services; examination and testing of genes for scientific research purposes; developmentexamination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; developmentexamination and testing of medicaments products; development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medicalpharmaceutical and biopharmaceutical field; development of gene databases; research and development services in the creation of databases and collections of information on biologicalsgenetic materialgenetic informationchemicals and compounds for research purposes; providing biological and medical research information; providing scientific research information and data in relation to health and disease state; medical research into personalised medicine; medical research services in the field of personalised diagnosticsmedical research services in the field of personal medical profiles; provision of scientific research information in the field of personalised medicine; pharmaceutical drug development services; consultancy and advisory relating to all the aforesaid services
Classe 44
Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticalsnamely pharmaceutical compounding services for others; providing personalised medicine services and personalised medical diagnostic reporting services; providing personal medical information; provision of medical information; provision of information to enable human diagnosis of medical conditions; providing medical information to enable healthcare professionals to enable the monitoring of patients; providing medical information to healthcare professionals to enable the assessment of progress in disease and treatment; consultancy and advisory relating to all the aforesaid services
Publicações
Histórico de despachos e eventos da marca no USPTO.
38 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/09/2022
FIMP
FINAL DISPOSITION PROCESSED
02/09/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
26/07/2022
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
27/05/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
26/04/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/02/2022
PUBO
PUBLISHED FOR OPPOSITION
08/02/2022
GPNX
NOTIFICATION PROCESSED BY IB
06/02/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
20/01/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
20/01/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
20/01/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
19/01/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
19/01/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/01/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/01/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
23/12/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
23/12/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
23/12/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
23/12/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
22/12/2021
GNFR
FINAL REFUSAL E-MAILED
22/12/2021
CNFR
FINAL REFUSAL WRITTEN
22/12/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/12/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/12/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/12/2021
RFNT
REFUSAL PROCESSED BY IB
11/07/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
21/06/2021
RFRR
REFUSAL PROCESSED BY MPU
21/06/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/06/2021
CNRT
NON-FINAL ACTION WRITTEN
11/06/2021
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
07/06/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
29/05/2021
CNRT
NON-FINAL ACTION WRITTEN
28/05/2021
DOCK
ASSIGNED TO EXAMINER
28/05/2021
MAFR
APPLICATION FILING RECEIPT MAILED
30/03/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
26/03/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
25/03/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ADRESTIA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.